191 related articles for article (PubMed ID: 21955084)
21. Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation.
Morita S; Yamamoto H; Sugitani Y
Stat Med; 2014 Oct; 33(23):4008-16. PubMed ID: 24820639
[TBL] [Abstract][Full Text] [Related]
22. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
Bonora E; Cigolini M
Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
[TBL] [Abstract][Full Text] [Related]
23. Bayesian analysis of transformation latent variable models with multivariate censored data.
Song XY; Pan D; Liu PF; Cai JH
Stat Methods Med Res; 2016 Oct; 25(5):2337-2358. PubMed ID: 24535555
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Ferdinand KC; Botros FT; Atisso CM; Sager PT
Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
[TBL] [Abstract][Full Text] [Related]
25. Seamlessly expanding a randomized phase II trial to phase III.
Inoue LY; Thall PF; Berry DA
Biometrics; 2002 Dec; 58(4):823-31. PubMed ID: 12495136
[TBL] [Abstract][Full Text] [Related]
26. Designing a Bayesian adaptive clinical trial to evaluate novel mechanical ventilation strategies in acute respiratory failure using integrated nested Laplace approximations.
Hosseini R; Chen Z; Goligher E; Fan E; Ferguson ND; Harhay MO; Sahetya S; Urner M; Yarnell CJ; Heath A
Contemp Clin Trials; 2024 Jul; 142():107560. PubMed ID: 38735571
[TBL] [Abstract][Full Text] [Related]
27. A practical Bayesian stepped wedge design for community-based cluster-randomized clinical trials: The British Columbia Telehealth Trial.
Cunanan KM; Carlin BP; Peterson KA
Clin Trials; 2016 Dec; 13(6):641-650. PubMed ID: 27430710
[TBL] [Abstract][Full Text] [Related]
28. Bayesian sample size determination for a Phase III clinical trial with diluted treatment effect.
Zhang YY; Ting N
J Biopharm Stat; 2018; 28(6):1119-1142. PubMed ID: 29513608
[TBL] [Abstract][Full Text] [Related]
29. Bayesian inference for kappa from single and multiple studies.
Basu S; Banerjee M; Sen A
Biometrics; 2000 Jun; 56(2):577-82. PubMed ID: 10877319
[TBL] [Abstract][Full Text] [Related]
30. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N
Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
[TBL] [Abstract][Full Text] [Related]
32. Bayesian adaptive dose-finding studies with delayed responses.
Fu H; Manner D
J Biopharm Stat; 2010 Sep; 20(5):1055-70. PubMed ID: 20721791
[TBL] [Abstract][Full Text] [Related]
33. Goodness-of-fit diagnostics for Bayesian hierarchical models.
Yuan Y; Johnson VE
Biometrics; 2012 Mar; 68(1):156-64. PubMed ID: 22050079
[TBL] [Abstract][Full Text] [Related]
34. Considerations for design and data analysis of noninferiority/superiority cardiovascular trials.
Quan H; Li M; Zhao PL; Cho M; Zhang J; Wu Y
J Biopharm Stat; 2013; 23(1):239-60. PubMed ID: 23331234
[TBL] [Abstract][Full Text] [Related]
35. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
36. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.
Zhao L; Woodworth G
Stat Med; 2009 Apr; 28(9):1339-52. PubMed ID: 19226557
[TBL] [Abstract][Full Text] [Related]
37. Sample size calculation for clinical trials analyzed with the meta-analytic-predictive approach.
Qi H; Rizopoulos D; van Rosmalen J
Res Synth Methods; 2023 May; 14(3):396-413. PubMed ID: 36625478
[TBL] [Abstract][Full Text] [Related]
38. The choice of prior distribution for a covariance matrix in multivariate meta-analysis: a simulation study.
Hurtado Rúa SM; Mazumdar M; Strawderman RL
Stat Med; 2015 Dec; 34(30):4083-104. PubMed ID: 26303671
[TBL] [Abstract][Full Text] [Related]
39. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
[TBL] [Abstract][Full Text] [Related]
40. Cardiovascular Mortality of Oral Antidiabetic Drugs Approved Before and After the 2008 US FDA Guidance for Industry: A Systemic Review and Meta-Analysis.
Goyat R; Rai P; Chang J; Ponte CD; Tan X
Clin Drug Investig; 2018 Jun; 38(6):491-501. PubMed ID: 29564723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
